ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

ClinicalTrials.gov ID: NCT04128579

Public ClinicalTrials.gov record NCT04128579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Multiple Ascending-dose Study of EQ001 in Subjects With Systemic Lupus Erythematosus With or Without Active Proliferative Lupus Nephritis

Study identification

NCT ID
NCT04128579
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Equillium
Industry
Enrollment
52 participants

Conditions and interventions

Interventions

  • Itolizumab [Bmab 600] Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2019
Primary completion
Nov 15, 2023
Completion
Jan 17, 2024
Last update posted
Apr 17, 2025

2019 – 2024

United States locations

U.S. sites
19
U.S. states
7
U.S. cities
17
Facility City State ZIP Site status
AKDHC Medical Research Services, LLC Sun City Arizona 85351
California Institute of Renal Research Chula Vista California 91910
University of California San Diego Perlman Ambulatory Clinic La Jolla California 92037
Clinical Research of West Florida - Clearwater Clearwater Florida 33765-2616
Centre for Rheumatology, Immunology and Arthritis Fort Lauderdale Florida 33309
University of Florida, Division of Rheumatology Gainesville Florida 32610
Clinical Site Partners Leesburg, LLC Leesburg Florida 34748
SouthCoast Research Center Inc Miami Florida 33136
Hope Clinical Trials Miami Florida 33165
Omega Research Maitland, LLC Orlando Florida 32810
Clinical Research of West Florida - Tampa Tampa Florida 33603
University of South Florida Tampa Florida 33606
Georgia Nephrology Lawrenceville Georgia 30046
Northwell Health / Division of Rheumatology Great Neck New York 11021
Columbia University Medical Center, Div of Nephrology New York New York 10032
Albert Einstein College of Medicine, Montefiore Medical Center The Bronx New York 10461
Northeast Clinical Research Center, LLC Bethlehem Pennsylvania 18017
Dallas Renal Group Dallas Texas 75230
Prolato Clinical Research Center (PCRC) Houston Texas 77054

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04128579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 17, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04128579 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →